RxDoctor Payments Data

Hiba Shakir

Physician Assistant · El Cajon, CANPI 1437834934

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 28 payments — averaging $38.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$247
  • Boston Scientific$172
  • Edwards Lifesciences$150
  • Alnylam Pharmaceuticals Inc.$144
  • Shield Therapeutics Inc$107
  • Pfizer$97
  • plus $164 from 4 others

What the payments were for

  • Food & beverage$1,081100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 70th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$803
Medicare patients
15
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$73,067
OzempicSemaglutide72$64,333
JanuviaSitagliptin Phosphate74$56,828
RybelsusSemaglutide50$46,141
XareltoRivaroxaban13$12,365
FarxigaDapagliflozin Propanediol13$10,086
EliquisApixaban13$8,841
LinzessLinaclotide16$8,311
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$6,937
Repatha SureclickEvolocumab11$6,757
TradjentaLinagliptin12$5,631
Celecoxib42$2,172
Albuterol Sulfate HfaAlbuterol Sulfate41$2,050
Rosuvastatin Calcium98$1,609
Diclofenac Sodium69$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$52$110,474122 claims
PfizerEliquis$97$8,84113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,423 physician assistant providers in California.

Other physician assistant in El Cajon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →